Jessica Spark
A5046887427- Schizophrenia research and treatment
- Mental Health Research Topics
- Mental Health and Psychiatry
- Psychosomatic Disorders and Their Treatments
- Treatment of Major Depression
- Personality Disorders and Psychopathology
- Functional Brain Connectivity Studies
- Pharmaceutical studies and practices
- Child and Adolescent Psychosocial and Emotional Development
- Psychotherapy Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Psychiatric care and mental health services
- Neurobiology of Language and Bilingualism
- Mindfulness and Compassion Interventions
- Mental Health and Patient Involvement
- Obsessive-Compulsive Spectrum Disorders
- Cannabis and Cannabinoid Research
- Bipolar Disorder and Treatment
- Diet and metabolism studies
- Tryptophan and brain disorders
- Advanced Neuroimaging Techniques and Applications
Orygen
2021-2025
The University of Melbourne
2021-2025
Orygen Youth Health
2020-2024
Griffith University
2013
Abstract This article describes the rationale, aims, and methodology of Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). is largest international collaboration to date that will develop algorithms predict trajectories outcomes individuals at clinical high risk (CHR) for psychosis advance development use novel pharmacological interventions CHR individuals. We present a description participating research networks data processing analysis coordination center, their processes...
Abstract Modern research management, particularly for publicly funded studies, assumes a data governance model in which grantees are considered stewards rather than owners of important sets. Thus, there is an expectation that collected shared as widely possible with the general community. This presents problems complex studies involve sensitive health information. The latter requires balancing participant privacy needs Here, we report on operation ecosystem crafted Accelerating Medicines...
Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk psychosis.
Cognitive impairment occurs at higher rates in individuals clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance multivariate prediction models of transition psychosis. Such is considered a core biomarker schizophrenia. Thus, cognition key domain measured the Accelerating Medicines Partnership® program Schizophrenia (AMP SCZ initiative). The aim this paper describe rationale, processes, considerations, final harmonization cognitive battery used...
Current treatments for schizophrenia and other psychotic disorders have limited efficacy, with high rates of nonresponse to "gold standard" treatments. New approaches are therefore urgently required. The aims this pilot study investigate the feasibility, acceptability, safety, usability Hybrid treatment (primary aim); explore Hybrid's efficacy engagement targets (secondary aim). primary aim will be assessed via face-to-face user experience surveys on a (self-assessed) 5-point Likert scale...
Mindfulness has become an increasingly popular intervention or adjunct therapy but little is known about whether mindfulness attributes normally develop with healthy ageing. Despite many negative stereotypes, evidence consistently emerging that one of the few benefits ageing may be enhanced psychological well-being. Although been reported as important predictor well-being, research on in older adults scarce. One reason improve well-being which not systematically examined elders more mindful....
To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome psychosis (CHR-P): Structured Interview Psychosis-risk Syndromes (SIPS) Comprehensive Assessment of At-Risk Mental States (CAARMS).
Abstract Background No biological treatment has been firmly established for the at‐risk stage of psychotic disorder. In this study we aim to test if subthreshold symptoms can be effectively treated with cannabidiol (CBD), a non‐psychoactive compound plant Cannabis sativa . The question taken on increased importance in wake evidence questioning both need and efficacy specific pharmacological interventions ultra‐high risk (UHR) psychosis group. Methods Three‐arm randomized controlled trial 405...
Abstract Aim Research has shown that preventative intervention in individuals at ultra‐high risk of psychosis (UHR) improves symptomatic and functional outcomes. The staged treatment early (STEP) trial aims to determine the most effective type, timing sequence interventions UHR population by sequentially studying effectiveness (1) support problem solving, (2) cognitive‐behavioural case management (3) antidepressant medication with an embedded fast‐fail option (4) omega‐3 fatty acids or...
Since the late 1990s, there has been a worldwide surge of scientific interest in pre-psychotic phase, resulting introduction several clinical tools for early detection. The predictive accuracy these limited, motivating need methodological and perspectival improvements. EASE manual supports systematic assessment anomalous self-experience, proposes an overall model understanding how most psychotic experiences may be initially generated on basis unifying, fundamental, pre-reflective distortion...
Several multivariate prognostic models have been published to predict outcomes in patients with first episode psychosis (FEP), but it remains unclear whether those predictions generalize independent populations. Using a subset of demographic and clinical baseline predictors, we aimed develop externally validate different predicting functional outcome after FEP the context schizophrenia-spectrum disorder (FES), based on previously cross-validation machine learning pipeline. A crossover...
Abstract Many individuals with psychotic symptoms have less complex language than healthy individuals. Word etymology is a lexical feature that has not yet been studied in clinical populations, but among individuals, words of Old French origin are chosen over Germanic-origin to convey formality (e.g. “inquire” vs. “ask”). Differences complexity may relate differences etymological content speech. Here, we determined the proportion word use and Old-French-origin large cohort recent-onset...
Prior qualitative studies show that individuals with psychoticlike experiences express difficulties concerning their identity. However, previous work has studied at clinical high risk for psychosis (CHR) and first-episode (FEP) separately. Here, we compare the of CHR, FEP, healthy individuals.
Abstract Background Almost 40% of individuals at ultra-high risk (UHR) for psychosis experience persistent attenuated psychotic symptoms (APS) yet it is unclear (1) whether they share overlapping clinical and functional outcomes compared to who transition psychosis, (2) when symptom functioning trajectories begin diverge between UHR with different outcomes, (3) non-remission (persistent APS or transition) can be predicted using baseline and/or longitudinal data. Study Design Participants...
<sec> <title>BACKGROUND</title> Current treatments for schizophrenia and other psychotic disorders have limited efficacy, with high rates of nonresponse to “gold standard” treatments. New approaches are therefore urgently required. </sec> <title>OBJECTIVE</title> The aims this pilot study investigate the feasibility, acceptability, safety, usability Hybrid treatment (primary aim); explore Hybrid’s efficacy engagement targets (secondary aim). primary aim will be assessed via face-to-face user...
Abstract Background Although approximately twenty randomised controlled trials have now been conducted with young people identified as being at high clinical risk of psychotic disorder, it remains unclear what the optimal type and sequence treatments are for this population. There has also increased focus on outcomes other than transition to such psychosocial functioning, persistent attenuated symptoms non-psychotic disorders. At Orygen, we currently conducting a trial interventions...